ImmunityBio Stock In Focus After FDA Expands Anktiva Bladder Cancer Approval

• ImmunityBio reported that long term data from the QUILT-3.032 trial in BCG unresponsive non muscle invasive bladder cancer supported the U.S. FDA’s expanded approval of ANKTIVA plus BCG to cover papillary only disease, with durable complete responses, high progression free survival at three years and a generally low rate of high grade treatment related adverse events.
• The broadened ANKTIVA label, now covering the full BCG unresponsive NMIBC population, materially widens ImmunityBio’s treated patient pool. In addition, the multi year durability and safety data from QUILT 3.032 strengthen the clinical foundation behind that expansion.
• The focus now turns to how ImmunityBio’s broader ANKTIVA label in BCG unresponsive NMIBC could reshape the medium term investment narrative.

Spot opportunities in other immunotherapy and oncology players by scanning our hand picked 20 high quality undiscovered gems that may also be flying under the radar after catalyst driven label changes.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, investors need to be comfortable with a story that is still concentrated in ANKTIVA and heavily dependent on execution in bladder cancer while the broader pipeline remains in development. The expanded NMIBC label and long term QUILT 3.032 data speak directly to that focus, since they relate to durability, safety and breadth of the current commercial opportunity.

In the near term, the key swing factor is how effectively ImmunityBio converts the broader U.S. indication into treated patients and reimbursed sales while managing costs in an unprofitable business with negative equity. The biggest risk stays the same: ANKTIVA remains the primary revenue engine while multiple new indications and geographies are still unproven.

The October 2026 FDA label expansion for ANKTIVA in BCG unresponsive NMIBC with papillary only tumors looks most relevant. It aligns with the long term Journal of Urology data and turns ANKTIVA into a treatment option for the full BCG unresponsive NMIBC population, which directly links to ImmunityBio’s operating focus in bladder cancer.

For catalysts, investor attention is likely to sit on how this broader indication translates into prescription trends, formulary access and international partner demand, against a backdrop of continued losses and heavy investment in new trials. Execution risk remains meaningful. If uptake, reimbursement or competitive pressures disappoint, the concentration in ANKTIVA could weigh on ImmunityBio’s broader ambitions.

ImmunityBio's narrative projects revenues of US$1.5b and earnings of US$688.6 million by 2029, which implies revenue growth of 106.7% per year and an earnings swing of about US$1.7b from a loss of US$992.4 million today to the forecast level.

Explore how ImmunityBio's fair value reflects a 55% potential upside compared with its current price before the market closes that gap.

Exploring Other Perspectives

One alternate angle to watch is reimbursement risk. Before this label expansion, the most optimistic analysts were already penciling in US$1.9b of revenue and US$868.3 million of earnings by 2029, far above consensus. That bullish view has not factored in the new data or broader ANKTIVA label yet, so expectations could shift meaningfully.

Explore 4 other ImmunityBio fair value estimates, including one that suggests potential upside of up to 503% from the current price.

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for ImmunityBio. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate ImmunityBio's overall financial health at a glance.

Looking For More Investment Ideas Beyond ImmunityBio?

ImmunityBio may be the headline today, but your portfolio benefits when you line it up against other opportunities with different risk and return profiles. Use the Simply Wall St Screener to scan wider and see where the numbers and business quality look most compelling for you.

• If you want potential mispricing with strong fundamentals, start by reviewing 33 high quality undervalued stocks that combine quality metrics with cheaper valuations.
• For investors who care about balance sheet strength first, filter for companies in the list of solid balance sheet and fundamentals (25 results) to see which businesses pair financial resilience with solid operating profiles.
• When you are hunting for opportunities the market might be overlooking, widen your search with our 20 high quality undiscovered gems and see which stories could deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com